Fig. 5: In vitro maturation status of DC2.4 cells after 24 hr treatment with VC-13 and its components.
From: A synthetic cyclic peptide for promoting antigen presentation and immune activation
The efficacy of VC-13 was evaluated by analysing the expression of surface markers CD40, MHC II, CD80, and CD86 using flow cytometry. a, b Percentage and MFI of CD40 expression in live DC2.4 cells. c, d Percentage and MFI of MHC II expression in live DC2.4 cells. e, f MFI and histograms of CD86 expression in live DC2.4 cells. g, h Percentage and MFI of CD80 expression in live DC2.4 cells. The histograms in (f) and (h) include a fluorescence minus one (FMO) signal represented by dark grey histograms. Histogram colours correspond to the samples in the charts. Statistical significance was determined using a one-way ANOVA (*, p < 0.05; ****, p < 0.0001).
